Skip to main content
. 2009 Feb 9;27(8):1168–1176. doi: 10.1200/JCO.2008.18.1024

Fig 2.

Fig 2.

Disease-free survival (DFS) among patients treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC) or docetaxel, doxorubicin, and cyclophosphamide (TAC) according to biologic subtype. Disease-free survival is shown in patients classified as (A) triple negative, (B) HER2, (C) luminal B, or (D) luminal A treated with FAC or TAC. P values in each panel are logistic regression calculations based on 3-year DFS. ER, estrogen receptor; PR, progesterone receptor.